Depression in Osteoarthritis: Current Understanding

Shen-Tao Wang,Guo-Xin Ni

DOI: https://doi.org/10.2147/NDT.S346183

IF: 2.989

2022-02-22

Neuropsychiatric Disease and Treatment

Abstract:Shen-Tao Wang, Guo-Xin Ni School of Sport Medicine and Rehabilitation, Beijing Sport University, Beijing, People's Republic of China Correspondence: Guo-Xin Ni, Tel +86-10-62989780, Fax +86-10-62989670, Email Depression, one of the most common comorbidities with osteoarthritis (OA), affects patient prognosis and quality of life. It also increases the overall burden of disease. This subgroup of patients has not been effectively managed in clinical settings. The study aimed to direct physicians' attention to the co-occurrence of depression and OA. Therefore, this review summarizes the relevant literature published over the past 10 years. The focus is on the prevalence of and risk factors for depression in OA, the effects of depression on OA development and treatment response, comorbidity mechanisms, screening, and non-pharmacological treatment. The research on the etiology of depression has been driven largely by epidemiological studies. Recent studies have shown that high levels of pain, poor levels of function, high numbers of OA sites, and slow gait might be associated with depression. However, the pathophysiology of OA and depression comorbidities remains unclear. In addition to immune inflammation and structural changes in the brain, which have been documented in brain imaging studies, psychosocial factors may also play a role. The evidence indicates that depression can be treated with early intervention; however, adjustments may need to be made for individuals with comorbid depression in OA. It is recommended that health care providers pay more attention to depressive symptoms in patients with OA. Clinicians should develop and implement an individualized and comprehensive treatment plan for patients based on a mental health assessment and in teams with other professionals to optimize treatment outcomes. Keywords: osteoarthritis, depression, epidemiology, prognosis, screening, treatment Osteoarthritis (OA), a chronic joint disease characterized by pain and limited mobility, affects over 300 million people worldwide. 1 According to the disease cost calculation method of Puig-Junoy et al, the social cost of OA may be 0.25% to 0.50% of a country's Gross Domestic Product. 2 There is consensus around the concern that the overall burden of OA will increase as the population ages. 3 Depression is common in people with OA, with a prevalence of 20%. 4 In 2020, a multicenter cross-sectional study conducted in Australia and the United States that included 19,110 participants found that compared to the non-OA group, the Odds ratio (OR) for depressive symptoms in the OA group was 1.41 [(95% confidence interval (CI) = 1.27–1.57). 5 The reported prevalence of depression among patients treated with total shoulder arthroplasty increased from 5.1% in 2002 to 15.4% in 2012. 6 This represents an almost three-fold increase. A similar trend has been observed among patients with total knee arthroplasty (TKA). 7 Considering the large population of patients with OA, a small percentage translates into a significant number of people. Of concern is the accumulating evidence that depression negatively affects prognosis, 7 healthcare expenditures, 8 and quality of life (QoL). 9 Specifically, individuals with both OA and depression have 38.8% higher direct medical costs than those with only OA. 8 Data from the 2014 Japanese National Health and Wellness Survey showed significant differences in Health-related quality of life (HRQoL), work productivity barriers, and health care resource utilization between those with and without moderate to severe depression, even after adjusting for potential confounders. 9 The public health implications of these findings are vast, as it is suggested that depression exacerbates the health-related burden of OA and that more attention should be paid to depression in people with OA. However, depression is often neglected. In particular, identification and diagnosis of depression is more difficult when prominent somatic symptoms of OA obscure less obvious depressive symptoms. 8,10 These sobering and salient evidence emphasize the pressing need for a deeper understanding of this relationship. Since a large number of studies has investigated the bidirectional relationship between OA and depression over the years, we have seen the need for a more up-to-date review. This narrative review aimed to (1) summarize the relevant epidemiologic literature; (2) explore the effects of depression on the onset, progression, and prognosis of OA and determine the mechanisms of OA with comorbid depression; and (3) discuss the extant knowledge on depression screening and nonpharmacological treatments in OA. At the broadest level, a large and still growing literature documents the associatio -Abstract Truncated-

psychiatry,clinical neurology